DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
Frank A. Sinicrope(Mayo Clinic in Arizona), Daniel J. Sargent(National Institute of Agricultural Botany), Steven Gallinger(University Health Network), G Monges(University Health Network), Greg Yothers(University of Pittsburgh), Carmen J. Allegra(National Cancer Institute), Silvia Marsoni(IFOM), Roberto Labianca(Ospedale Papa Giovanni XXIII), Malcolm J. Moore(University Health Network), Stephen N. Thibodeau(Mayo Clinic in Arizona), Nathan R. Foster(University Health Network)
Cited by 527
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k